The EGF/GBS Clinical Trial Is Only a Part of It. About the GBS trial, it's a proof-of-concept trial, and success, though important, may not not be that immediately beneficial for Bioasis, at least not on its own. If Bioasis doesn't have an expanded storyboard that includes at least some resolution of the advancement of xB3-001, 004 and progranulin, and news of some business and scientific success with at least a couple of Bioasis's many partners, then this isn't going to Nasdaq any time soon.
I think there is an expanded storyboard that will make a GBS trial look exactly like what it is, proof that the acquisition of the EGF platform provides Bioasis with meaningful future xB3 payloads while allowing Bioasis to immediately call itself a "clinical stage" company. It's a big and important step for any company to enter human clinical trials and a GBS/EGF clinical trial would help legitimize Bioasis.
But in the end, it's all about xB3 and the delivery across the BBB of xB3 payloads that can treat a large variety of neuro-disorders. That's the sizzle to this steak. It's what allows comparison to Denali, something, if you'll notice, that Bioasis is doing with increasing frequency and intensity. I believe that Ladenburg Thalmann and others see Denali as the model, and Denali's success as the goal for Bioasis.
A successful proof-of-concept GBS trial is a check mark on a list of several required Bioasis accomplishments. It tells the investing world that Bioasis is serious and clinically successful, but GBS/EGF, by itself, is not sufficiently differentiating. It will be xB3-drug announcements that will make Bioasis look like a credible investing vehicle for blockbuster returns to investors. I believe that's the plan and the play, with Cresence being the first of several storyboard announcements to be made in the months ahead.
The investing world has a "tire-kicking" attitude about xB3, that xB3 has never been tested and proven. And, frankly, that's true. The acquisition of the EGF platform has caused some people to think that Bioasis has given up on xB3. Using the word "shelved" in the xB3 brain tumour context was and remains a disaster. We're going to learn that there was no damn need to use that word. The EGF platform has also been poorly explained, as has the upcoming EGF clinical trial. I'll soon have some stuff to say about the EGF stuff.
The setup appears to be on to get some really high valuations for Bioasis and its programs. Saying that we can't get there from here (10¢) is nonsense.
jd